Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis

mAbs

Volumn 8, Issue 5, 2016, Pages 892-904

  Lee, Dongheon ^a,b   Kim, Dongin ^a   Choi, Yu Bin ^a   Kang, Kyungjae ^a   Sung, Eun Sil ^a,b   Ahn, Jin Hyung ^a,b   Goo, Junseo ^a   Yeom, Dong Hoon ^a   Jang, Hyun Sook ^a   Moon, Kyung Duk ^a   Lee, Sang Hoon ^a,b   You, Weon Kyoo ^a,b  

^a Hanwha Corporation   (South Korea)

^b ABL Bio   (South Korea)

Author keywords

Anti angiogenesis; anti cancer; biologics; delta like ligand; therapeutic antibody; VEGF

Indexed keywords

BEVACIZUMAB; DELTA LIKE LIGAND 4; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; DLL4 PROTEIN, HUMAN; SIGNAL PEPTIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; GENE CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SIZE EXCLUSION CHROMATOGRAPHY; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84966874363     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1171432     Document Type: Article

References (30)

1. G.Neufeld, T.Cohen, S.Gengrinovitch, Z.Poltorak. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22; PMID:9872925
2. K.L.Meadows, H.I.Hurwitz. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012; 2:a006577; PMID:23028128; http://dx.doi.org/10.1101/cshperspect.a006577
3. S.J.Casak, I.Fashoyin-Aje, S.J.Lemery, L.Zhang, R.Jin, H.Li, L.Zhao, H.Zhao, H.Zhang, H.Chen, et al. FDA Approval Summary: Ramucirumab for Gastric Cancer. Clin Cancer Res 2015; 21:3372-6; PMID:26048277; http://dx.doi.org/10.1158/1078-0432.CCR-15-0600
4. G.Trichonas, P.K.Kaiser. Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther. 2013; 2:89-98; PMID:25135809; http://dx.doi.org/10.1007/s40123-013-0015-2
5. G.Bergers, D.Hanahan. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603; PMID:18650835; http://dx.doi.org/10.1038/nrc2442
6. S.E.Abdullah, R.Perez-Soler. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 2012; 118:3455-67; PMID:22086782; http://dx.doi.org/10.1002/cncr.26540
7. M.Pàez-Ribes, E.Allen, J.Hudock, T.Takeda, H.Okuyama, F.Viñals, M.Inoue, G.Bergers, D.Hanahan, O.Casanovas. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027
8. J.M.Ebos, C.R.Lee, W.Cruz-Munoz, G.A.Bjarnason, J.G.Christensen, R.S.Kerbel. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9; PMID:19249681; http://dx.doi.org/10.1016/j.ccr.2009.01.021
9. H.Hashizume, B.L.Falcón, T.Kuroda, P.Baluk, A.Coxon, D.Yu, J.V.Bready, J.D.Oliner, D.M.McDonald. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70:2213-23; PMID:20197469; http://dx.doi.org/10.1158/0008-5472.CAN-09-1977
10. W.K.You, B.Sennino, C.W.Williamson, B.Falcón, H.Hashizume, L.C.Yao, D.T.Aftab, D.M.McDonald. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011; 71:4758-68; PMID:21613405; http://dx.doi.org/10.1158/0008-5472.CAN-10-2527
11. N.W.Gale, M.G.Dominguez, I.Noguera, L.Pan, V.Hughes, D.M.Valenzuela, A.J.Murphy, N.C.Adams, H.C.Lin, J.Holash, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 2004; 101:15949-54; PMID:15520367; http://dx.doi.org/10.1073/pnas.0407290101
12. I.Noguera-Troise, C.Daly, N.J.Papadopoulos, S.Coetzee, P.Boland, N.W.Gale, H.C.Lin, G.D.Yancopoulos, G.Thurston. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444:1032-7; PMID:17183313; http://dx.doi.org/10.1038/nature05355
13. J.Ridgway, G.Zhang, Y.Wu, S.Stawicki, W.C.Liang, Y.Chanthery, J.Kowalski, R.J.Watts, C.Callahan, I.Kasman, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444:1083-7; PMID:17183323; http://dx.doi.org/10.1038/nature05313
14. F.Kuhnert, J.R.Kirshner, G.Thurston. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell 2011; 3:20; PMID:21923938; http://dx.doi.org/10.1186/2045-824X-3-20
15. R.C.Sainson, A.L.Harris. Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med 2007; 13:389-95; PMID:17822956; http://dx.doi.org/10.1016/j.molmed.2007.07.002
16. K.M.Miles, M.Seshadri, E.Ciamporcero, R.Adelaiye, B.Gillard, P.Sotomayor, K.Attwood, L.Shen, D.Conroy, F.Kuhnert, et al. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. PLoS One 2014; 9:e112371; PMID:25393540; http://dx.doi.org/10.1371/journal.pone.0112371
17. T.Kuramoto, H.Goto, A.Mitsuhashi, S.Tabata, H.Ogawa, H.Uehara, A.Saijo, S.Kakiuchi, Y.Maekawa, K.Yasutomo, et al. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-κB activity. Mol Cancer Ther 2012; 11:2578-87; PMID:22989420; http://dx.doi.org/10.1158/1535-7163.MCT-12-0640
18. D.W.Jenkins, S.Ross, M.Veldman-Jones, I.N.Foltz, B.C.Clavette, K.Manchulenko, C.Eberlein, J.Kendrew, P.Petteruti, S.Cho, et al. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol Cancer Ther 2012; 11:1650-60; PMID:22679110; http://dx.doi.org/10.1158/1535-7163.MCT-11-1027
19. J.L.Li, R.C.Sainson, C.E.Oon, H.Turley, R.Leek, H.Sheldon, E.Bridges, W.Shi, C.Snell, E.T.Bowden, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011; 71:6073-83; PMID:21803743; http://dx.doi.org/10.1158/0008-5472.CAN-11-1704
20. F.Kuhnert, G.Chen, S.Coetzee, N.Thambi, C.Hickey, J.Shan, P.Kovalenko, I.Noguera-Troise, E.Smith, J.Fairhurst, et al. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer. Cancer Res 2015; 75:4086-96; PMID:26377940; http://dx.doi.org/10.1158/0008-5472.CAN-14-3773
21. T.Hoey, W.C.Yen, F.Axelrod, J.Basi, L.Donigian, S.Dylla, M.Fitch-Bruhns, S.Lazetic, I.K.Park, A.Sato, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5:168-77; PMID:19664991; http://dx.doi.org/10.1016/j.stem.2009.05.019
22. J.S.Marvin, Z.Zhu. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 2005; 26:649-58; PMID:15916729; http://dx.doi.org/10.1111/j.1745-7254.2005.00119.x
23. J.S.Michaelson, S.J.Demarest, B.Miller, A.Amatucci, W.B.Snyder, X.Wu, F.Huang, S.Phan, S.Gao, A.Doern, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. mAbs 2009; 1:128-41; PMID:20061822; http://dx.doi.org/10.4161/mabs.1.2.7631
24. D.E.Milenic, T.Yokota, D.R.Filpula, M.A.Finkelman, S.W.Dodd, J.F.Wood, M.Whitlow, P.Snoy, J.Schlom. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991; 51:6363-71; PMID:1933899
25. Y.Zhou, A.L.Goenaga, B.D.Harms, H.Zou, J.Lou, F.Conrad, G.P.Adams, B.Schoeberl, U.B.Nielsen, J.D.Marks. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther 2012; 11:1467-76; PMID:22564724; http://dx.doi.org/10.1158/1535-7163.MCT-11-1038
26. J.M.Clarke, H.I.Hurwitz. Understanding and targeting resistance to anti-angiogenic therapies. J Gastrointest Oncol 2013; 4:253-63; PMID:23997938; http://dx.doi.org/10.3978/j.issn.2078-6891.2013.036
27. W.C.Yen, F.Axelrod, C.Bond, J.Cain, C.Chartier, M.Fischer, S.Ma, R.Meisner, J.Raval, J.Shah. Dual targeting of DLL4 and VEGF signaling by a novel bispecific antibody inhibits tumor growth and reduces cancer stem cell frequency. AACR Annual Meeting 2014; 2014 April 5–9; San Diego, CA
28. A.L.Gurney, A.K.Sato. inventors; Oncomed Pharmaceuticals, Inc., assignee. Method for making heteromultimeric molecules. United States patent US2011/0123532 A1. 2011 May 26
29. H.Y.Yang, K.J.Kang, J.E.Chung, H.Shim. Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Mol Cells 2009; 27:225-35; PMID:19277506; http://dx.doi.org/10.1007/s10059-009-0028-9
30. M.K.Ki, K.J.Kang, H.Shim. Phage display selection of EGFR-specific antibodies by capture-sandwich panning. Biotechnology and Bioprocess Engineering 2010; 15:152-6; http://dx.doi.org/10.1007/s12257-009-3080-6